Abstract The coronavirus disease 2019 (COVID-19) vaccination will be the largest
vaccination programme in the history of the NHS. Patients on immunosuppressive therapy …

Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic.
Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with …

Patients with rheumatic diseases are at increased risk of infectious complications;
vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs …

Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …

To update the European League Against Rheumatism (EULAR) recommendations for
vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Objective To investigate the humoral and cellular immune response to messenger RNA
(mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases …

Objective To provide evidence‐based recommendations on the use of vaccinations in
children and adults with rheumatic and musculoskeletal diseases (RMDs). Methods This …

Objectives Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects
humoral immune response after vaccination. It remains unclear whether RTX-treated …

Background Patients on therapeutic immunosuppressants for immune-mediated
inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to …